glp-1 receptor agonist Agonists Impact of GLP- 1 Receptor

Four found energy intake to be significantly reduced, whereas the remaining studies failed to find an effect again potentially due to limited statistical power and also low GLP-1 infusion rates

SURPASS-AP-combo, respective clinical trial registration numbers NCT04537923, NCT04255433, NCT03861052, NCT03861039, NCT04093752) are not completed yet

initiated a Phase 3 clinical trial for its investigational GLP-1 agonist compound MariTide, targeting obesity and cardiometabolic comorbidities

95% CI 0.160.33) compared with the non-GLP-1 RAs group

One of the qualms about GLP1s is that they involve a weekly injection, and some people do not like needles

Equally, policy-driven studies are needed to evaluate cost-containment models, equitable access strategies, and the public health implications of widespread GLP-1RA adoption